Combination of anti-β2M mAbs (10 μg/mL) and BTZ (5 nM) was further evaluated in the MM cell lines ARK, ARP-1, MM.1S, and U266 in a 24-hour treatment. Here, B2M is linked to Miyoshi myopathy.